.png)
Послать статью по эл. почте 
ПЕРСОНАЛИЗИРОВАННЫЙ ПОДХОД, ДОКАЗАТЕЛЬСТВА, ПРАКТИКА (ПО МАТЕРИАЛАМ XXVI НАЦИОНАЛЬНОГО КОНГРЕССА ПО БОЛЕЗНЯМ ОРГАНОВ ДЫХАНИЯ)
https://doi.org/10.18093/0869-0189-2016-26-5-630-634
Аннотация
Об авторе
Е. Н. БарабановаРоссия
к. м. н., менеджер по медицинским и научным коммуникациям ЗАО «ГлаксоСмитКляйн Трейдинг»
Список литературы
1. Herland K., Akselsen J.P., Skjǿnsberg O.H. et al. How representative are clinical study patients with asthma or COPD for a larger "real life" population of patients with obstructive lung disease? Respir. Med. 2005; 99: 11–19.
2. Treweek S., Zwarenstein M. Making trials matter: pragmatic and explanatory trials and the problem of applicability. Trials. 2009; 10: 37.
3. Godwin M., Ruhland L., Casson I. et al. Pragmatic controlled clinical trials in primary care: the struggle between external and internal validity. BMC Med. Res. Methodol. 2003; 3: 28.
4. ABPI. The Vision for Real World Data – Harnessing the opportunities in the UK. White Paper, September 2011. Available at http://www.abpi.org.uk/our-work/library/industry/Documents/Vision-for-Real-World-Data.pdf
5. Bateman E.D., Boushey H.A., Bousquet J. et al. Can guideline-defined asthma control be achieved? The Gaining Optimal Asthma ControL study. Am. J. Respir. Crit. Care Med. 2004; 170: 836–844.
6. Busse W.W., Shailen R.S., Somerville L. et al. Comparison of adjustable- and fixed-dose budesonide/formoterol pressurized metered-dose inhaler and fixed-dose fluticasone propionate/salmeterol dry powder inhaler in asthma patients. J. Allergy Clin. Immunol. 2008; 121 (6): 1407–1414. DOI: 10.1016/j.jaci.2008.03.019.
7. Vestbo J., Anderson J.A., Calverley P.M.A. et al. Adherence to inhaled therapy, mortality and hospital admission in COPD. Thorax. 2009; 64: 939–943.
8. Papi A., Paggiaro P.L., Nicolini G. et al. Inhaled Combination Asthma Treatment versus SYmbicort (ICAT SY) Study Group: beclomethasone/formoterol versus budesonide/formoterol combination therapy in asthma. Eur. Respir. J. 2007; 29: 682–689.
9. Breekveldt-Postma N.S., Koerselman J., Erkens J.A. et al. Treatment with inhaled corticosteroids in asthma is too often discontinued. Pharmacoepidemiol. Drug Saf. 2008; 17: 411–422.
10. Janson C., de Marco R., Accordini S. et al. Changes in the use of anti-asthmatic medication in an international cohort. Eur. Respir. J. 2005; 26: 1047–1055.
11. Adams R.J., Fuhlbrigge A., Guilbert T. et al. Inadequate use of asthma medication in the United States: Results of the asthma in America national population survey. J. Allergy Clin. Immunol. 2002; 110: 58–64.
12. Ställberg B., Nystrom K.U., Olsson P. et al. Living with asthma in Sweden – the ALMA study. Respir. Med. 2003; 97: 835–843.
13. de Marco R., Cazzoletti L., Cerveri I. et al. Are the asthma guideline goals achieved in daily practice? A population-based study on treatment adequacy and the control of asthma. Int. Arch. Allergy Immunol. 2005; 138: 225–234.
14. Corrigan C.J. Asthma therapy: there are guidelines, and then there is real life. Prim. Care Respir. J. 2011; 20: 13–14.
15. Vestbo J., Leather D., Bakerly N.D. et al. Effectiveness of fluticasone furoate–vilanterol for COPD in clinical practice. N. Eng. J. Med. 2016; 375: 1253–1260.
16. Agusti A., Calverley P.M., Celli B. et al. Characterisation of COPD heterogeneity in the ECLIPSE cohort. Respir. Res. 2010; 11: 122.
17. Global Strategy for the Diagnosis, Management and Prevention of Chronic Obstructive Pulmonary Disease. GOLD, 2016. Available at www.goldcopd.com
18. Casanova C., Marin J.M., Martinez-Gonzalez C. et al. New GOLD classification: longitudinal data on group assignment. Respir. Res. 2014; 15: 3–12.
19. Nannini L.J., Lasserson T.J., Poole P. Combined corticosteroid and long-acting beta(2)-agonist in one inhaler versus long-acting beta(2)-agonists for chronic obstructive pulmonary disease. Cochrane Database Syst. Rev. 2012; (9): CD006829.
20. Nannini L.J., Poole P., Milan S.J. et al. Combined corticosteroid and long-acting beta(2)-agonist in one inhaler versus inhaled corticosteroids alone for chronic obstructive pulmonary disease. Cochrane Database Syst. Rev. 2013; (8): CD006826.
21. Dransfield M.T., Bourbeau J., Jones P.W. et al. Once-daily inhaled fluticasone furoate and vilanterol versus vilanterol only for prevention of exacerbations of COPD: two replicate double-blind, parallel-group, randomised controlled trials. Lancet Respir. Med. 2013; 1: 210–223.
22. Sharafkhaneh A., South J.G., Goldman M. et al. Effect of budesonide/formoterol pMDI on COPD exacerbations: a double-blind, randomized study. Respir Med. 2012; 106: 257–268.
23. Wedzicha J.A., Singh D., Vestbo J. et al. Extrafine beclomethasone/formoterol in severe COPD patients with history of exacerbations. Respir. Med. 2014; 108: 1153–1162.
24. Kardos P., Wencker M., Glaab T. et al. Impact of salmeterol/fluticasone propionate versus salmeterol on exacerbations in severe chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 2007; 175: 144–149.
25. EMA completes review of inhaled corticosteroids for chronic obstructive pulmonary disease. EMA/488280/2016. Available at http://www.ema.europa.eu/docs/en_GB/document_library/Referrals_document/Inhaled_corticosteroids_Article_31/European_Commission_final_decision/WC500210489.pdf
26. Siddiqui S.H., Guasconi A., Vestbo J. et al. Blood Eosinophils: A biomarker of response to extrafine beclomethasone/formoterol in chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 2015; 192: 523–525.
27. Pascoe S., Locantore N., Dransfield M.T. et al. Blood eosinophil counts, exacerbations, and response to the addition of inhaled fluticasone furoate to vilanterol in patients with chronic obstructive pulmonary disease: A secondary analysis of data from two parallel randomised controlled trials. Lancet Respir. Med. 2015; 3: 435–442.
28. Pavord I.D., Lettis S., Locantore N. et al. Blood eosinophils and inhaled corticosteroid/long-acting b2-agonist efficacy in COPD. Thorax. 2016; 7: 118–125.
29. Watz H., Tetzlaff K., Wouters E.F.M. et al. Blood eosinophil count and exacerbations in severe chronic obstructive pulmonary disease after withdrawal of inhaled corticosteroids: a post-hoc analysis of the WISDOM trial. Lancet Respir. Med. 2016; 4: 390–398.
30. Müllerová H., Lu C., Li H. et al. Prevalence and burden of breathlessness in patients with chronic obstructive pulmonary disease. PLoS ONE. 2014; 9 (1): e85540.
31. Buhl R., Maltais F., Abrahams R. et al. Tiotropium and olodaterol fixed-dose combination versus mono-components in COPD (GOLD 2–4). Eur. Respir. J. 2015; 45: 869–871.
32. Bateman E.D., Ferguson G.T., Barnes N. et al. Dual bronchodilation with QVA149 versus single bronchodilator therapy: the SHINE study. Eur. Respir. J. 2013; 42: 1484–1494.
33. Maleki-Yazdi M.R., Kaelin T., Richard N. et al. Efficacy and safety of umeclidinium/vilanterol 62.5/25 mcg and tiotropium 18 mcg in chronic obstructive pulmonary disease: results of a 24-week, randomized, controlled trial. Respir. Med. 2014; 108: 1752–1760.
34. Maleki-Yazdi M.R., Singh D., Anzueto A. et al. Assessing short-term deterioration in maintenance-naïve patients with COPD receiving umeclidinium/vilanterol and tiotropium: a pooled analysis of three randomized trials. Adv. Ther. 2017; 33: 2188–2199. Epub. Oct. 28, 2016.
35. Calzetta L., Matera M.G., Cazzola M. Pharmacological interaction between LABAs and LAMAs in the airways: optimizing synergy. Eur. J. Pharmacol. 2015; 761:168–173.
36. Agusti A. The path to personalized medicine in COPD. Thorax. 2014; 69: 857–864.
Дополнительные файлы
Для цитирования: Барабанова Е.Н. ПЕРСОНАЛИЗИРОВАННЫЙ ПОДХОД, ДОКАЗАТЕЛЬСТВА, ПРАКТИКА (ПО МАТЕРИАЛАМ XXVI НАЦИОНАЛЬНОГО КОНГРЕССА ПО БОЛЕЗНЯМ ОРГАНОВ ДЫХАНИЯ). Пульмонология. 2016;26(5):630-634. https://doi.org/10.18093/0869-0189-2016-26-5-630-634
For citation: Barabanova E.N. INDIVIDUALIZED APPROACH, EVIDENCE, PRACTICE (BASED ON PROCEEDINGS OF THE 26TH NATIONAL CONGRESS ON RESPIRATORY DISEASES). Russian Pulmonology. 2016;26(5):630-634. (In Russ.) https://doi.org/10.18093/0869-0189-2016-26-5-630-634
Обратные ссылки
- Обратные ссылки не определены.